Introduction
The morpholino unit is a privileged fragment 1 in numerous drugs 2 by virtue of its preferred chair conformation, oxygen lone pairs that can act as hydrogen bond acceptor(s) and a nitrogen atom that enables attachment to an aromatic or heteroaromatic scaffold. The importance of morpholino groups and especially their pseudoequatorial lone pair has recently been highlighted for inhibitors of phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs). 3 The interaction of the morpholino group of an inhibitor with its target was described as 'representing a cornerstone in drug development of novel PI3K inhibitors'. 3 To modulate the properties of a morpholino unit in such inhibitors, one or more of the methylene groups may be substituted, which has enabled selectivity to be achieved amongst members of the PI kinase families. Thus, selectivity for mTOR (the mammalian target of rapamycin) over PI3Kα, was attained by replacing a morpholino unit in certain pyrazolopyrimidines with the bridged morpholine 8-oxa-3-azabicyclo[3.2.1]octane 1a. 4 This morpholine analogue has also been used to introduce a bridged morpholino group into other compounds targeting mTOR, 5 as well as inhibitors of Aurora kinases 6 and glucokinase. 7 Such modifications permit the properties of inhibitors to be modulated, e.g. cLogP is increased and a subtle structural feature is incorporated. For the mTOR pyrazolopyrimidine inhibitors with a bridged morpholine in place of the parent morpholine, hydrophobic interactions with the kinase's critical 'hinge' region were enhanced. 
Results and Discussion
Owing to the current pharmaceutical interest in conformationally constrained ('bridged') morpholines, new synthetic methods to access these compounds have recently been developed. [8] [9] [10] Two exemplars are the bridged morpholines 8-oxa-3-aza-bicyclo[3.2.1]octane 1a and 9-oxa-3-aza-bicyclo[3.3.1]nonane 2a. The latter compound has only been described as N-substituted derivatives in patents.
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Compared to 1a, morpholine 2a provides a significant increase in cLogP (~ 0.4) and the possibility of an enhanced interaction at a hydrophobic binding site of a target protein.
The synthesis of 1a has been previously achieved by reducing 5-hydroxymethyl-2-furfural to 2,5-bis-hydroxymethyltetrahydrofuran, the di-p-toluenesulfonate of which was treated with ammonia (under pressure at 170 o C) or benzylamine. These methods either afforded 1a directly in very low yield [12] [13] [14] [15] [16] or in better yield (43-64%) via an intermediate N-benzyl compound, which was subjected to hydrogenolysis. 17 The latter synthesis was scaleable, but required two high-pressure hydrogenations. We have developed an efficient and rapid synthesis of 8-oxa-3-aza-bicyclo[3.2.1]octane 1a (Scheme 1) from furan-2,5-dicarboxylic acid 3 via 4 and 5 that avoids high-pressure hydrogenation steps and is solvent-free for the key cyclisation step. The synthesis was inspired by Komppa's classical route 18 to 3-aza-bicyclo[3.3.1]nonane 2b, whereby cis-cyclohexane-1,3-dicarboxylic acid 6b was neutralised with aqueous ammonia and the solution evaporated presumably to give 7b, which was heated at ~ 300 o C affording imide 8b. Compound 8b was reduced to 2b, either electrolytically under strongly acidic conditions 18 or with lithium aluminium hydride. 19 This route to 2b was modified in the manner described below for 1a, again starting from cis-cyclohexane-1,3-dicarboxylic acid and proceeding via 6b and 7b (see Scheme 2 and Supplementary Information). The route to 1a parallels that for 2b and is convenient on a laboratory scale, as well as being applicable to the synthesis of other bridged morpholines exemplified here by an analogous synthesis of 2a. Catalytic hydrogenation of furan-2,5-dicarboxylic acid 3 was performed at atmospheric pressure in acetic acid at 60 °C to give (2R,5S)-tetrahydrofuran-2,5-dicarboxylic acid 4, which was isolated as its crystalline diammonium salt in almost quantitative yield. The configuration of 4 was assigned by analogy with that of compound 6a (see below). Thermolysis of the di-ammonium salt of 4 using either microwave or conventional heating gave 8-oxa-3-azabicyclo[3.2.1]octane-2,4-dione 5 (Scheme 1). Optimisation of the reaction conditions enabled imide 5 to be prepared in up to 78% yield, using conventional heating of 4. A variety of solvents and conditions was explored for the conversion of 4 into 5, but none provided a higher yield than heating at 230 o C the melt derived from the neat solid of 4. Finally, reduction of imide 5 with borane gave the desired bridged morpholine 1a, which was isolated as its hydrochloride in 70% yield. None of the steps in this sequence required chromatographic purification. In a similar manner (Scheme 2), the readily available 4H-pyran-2,6-dicarboxylic acid 20 was reduced (H 2 , cat. Pd/C) to (2R,6S)-tetrahydro-2H-pyran-2,6-dicarboxylic acid 6a, which was isolated as crystals of the di-ammonium salt 7a. The configuration of the diacid was previously assigned by Cope and Fournier 20 and was confirmed by the crystal structure analysis (CCDC: 1471854; for data see Table 1 , Supplementary Information) of the di-ammonium salt 7a, which showed a chair conformer with both carboxyl groups equatorial ( Figure  1 ). In this structure the protons of the acid groups have been modelled as disordered over two positions along the intermolecular hydrogen bond vectors in such a way that the structure with the highest occupancy is a co-crystal of both the deprotonated and doubly-protonated forms. Thermolysis of 7a gave 9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 8a, which was reduced with borane to afford 9-oxa-3-azabicyclo The asymmetric unit of the crystal structure of 6a (di-ammonium salt). Only the carboxylic acid protons with the highest occupancy are shown for clarity. Thermal ellipsoids are drawn at the 50% probability level.
Conclusions
Syntheses of 8-oxa-3-aza-bicyclo[3.2.1]octane 1a and 9-oxa-3-aza-bicyclo[3.3.1]nonane 2a were each rapidly and simply achieved with an overall yield of 50-55% without any hazardous steps, laborious purifications or costly reagents. The key cyclisation step is solvent-free. The developed methodology was also used to prepare [2,2,4,4-2 H 4 ]8-oxa-3-aza-bicyclo[3.2.1]octane 1b (Scheme 1), which is potentially useful for metabolic studies of drugs containing the bridged morpholine unit derived from 1a. The method described is versatile being applicable to both cycloalkane-1,3-dicarboxylates 18, 19 and oxacycloalkane-1,3-dicarboxylates.
